Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma

por Nakamura, Ayano, Suzuki, Susumu, Kanasugi, Jo, Ejiri, Masayuki, Hanamura, Ichiro, Ueda, Ryuzo, Seto, Masao, Takami, Akiyoshi
Publicado 2021

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan

por Tsukiyama, Ikuto, Ejiri, Masayuki, Yamamoto, Yoshihiro, Nakao, Haruhisa, Yoneda, Masashi, Matsuura, Katsuhiko, Arakawa, Ichiro, Saito, Hiroko, Inoue, Tadao
Publicado 2016

Cost‐effectiveness of aprepitant in Japanese patients treated with cisplatin‐containing highly emetogenic chemotherapy

por Tsukiyama, Ikuto, Hasegawa, Shiori, Ikeda, Yoshiaki, Takeuchi, Masayuki, Tsukiyama, Sumiyo, Kurose, Yusuke, Ejiri, Masayuki, Sakuma, Masaki, Saito, Hiroko, Arakawa, Ichiro, Inoue, Tadao, Yamaguchi, Etsuro, Kubo, Akihito
Publicado 2018

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia

por Karnan, Sivasundaram, Hanamura, Ichiro, Ota, Akinobu, Takasugi, Souichi, Nakamura, Ayano, Takahashi, Miyuki, Uchino, Kaori, Murakami, Satsuki, Wahiduzzaman, Md, Quang Vu, Lam, Rahman, Md Lutfur, Hasan, Muhammad Nazmul, Hyodo, Toshinori, Konishi, Hiroyuki, Tsuzuki, Shinobu, Yoshikawa, Kazuhiro, Suzuki, Susumu, Ueda, Ryuzo, Ejiri, Masayuki, Hosokawa, Yoshitaka, Takami, Akiyoshi
Publicado 2021